Skip to main navigation Skip to search Skip to main content

Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia

  • Roswell Park Cancer Institute

Research output: Contribution to journalEditorial

6 Scopus citations
Original languageEnglish
Pages (from-to)2011-2013
Number of pages3
JournalLeukemia and Lymphoma
Volume59
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Dive into the research topics of 'Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this